Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 5/20 | 0.48 |
| ▸ | CES1 | P23141 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | PNLIP | P16233 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794231 | 1.00 | ERN1 (0.50) | ERN1CES2CES1POLBMAPT | |
| SCHEMBL22133771 | 0.87 | MEN1 (0.46) | ERN1CES2CES1POLBMAPT | |
| SCHEMBL30845519 | 0.87 | MEN1 (0.46) | ERN1CES2CES1POLBMAPT | |
| SCHEMBL6175690 | 0.81 | KEAP1 (0.42) | ERN1CES2CES1POLBMAPT | |
| SCHEMBL29467941 | 0.80 | CES2 (0.68) | ERN1CES2CES1MAOBSMN1; SMN2 | |
| SCHEMBL363749 | 0.80 | CES2 (0.68) | ERN1CES2CES1MAOBSMN1; SMN2 | |
| SCHEMBL2791251 | 0.80 | AKR1C2 (0.58) | ERN1CES2CES1MAPTMEN1 | |
| SCHEMBL29695966 | 0.80 | AKR1C2 (0.58) | ERN1CES2CES1MAPTMEN1 | |
| SCHEMBL7628578 | 0.79 | KEAP1 (0.41) | ERN1CES2CES1POLBMAPT | |
| SCHEMBL3713099 | 0.79 | AKR1C2 (0.42) | CES2CES1POLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118057638-A | Carbon-supported metal-nonmetal diatomic catalytic couple material, and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2024-05-21 | — | — | CN | claimed |
| CN-114751870-A | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and derivative thereof, and synthesis method and application thereof | 贵州医科大学 | 2022-07-15 | — | — | CN | claimed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| EP-4743456-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-122029160-A | Method for preparing PI3K inhibitor | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU LANGRUI BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| WO-2025201503-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2025-10-02 | — | — | WO | disclosed |
| US-6191164-B1 | POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | disclosed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | disclosed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | disclosed |
| EP-0807629-A1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-19 | — | — | EP | disclosed |
| US-3933472-A | Substituted alkylaryl ketones and methods of use as herbicides | BUCKMAN LABORATORIES, INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | ERN1 703/4885CES2 389/4885CES1 769/4885 |
| US-20260028352-A1 | MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | WEE2, WEE1, ROR1 | ERN1 1575/4885CES2 3561/4885CES1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.